[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506432":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":37,"locations":46,"responsibleParty":78,"collaborators":80,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":28,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":28,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":28,"overallStatus":48,"whyStopped":28,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Frontera Therapeutics","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose FT-002","EXPERIMENTAL","Intraocular injection of a single low dose of FT-002",[13],"Genetic: FT-002",{"label":15,"type":10,"description":16,"interventionNames":17},"Intermediate dose FT-002","Intraocular injection of a single Intermediate dose of FT-002",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"High dose FT-002","Intraocular injection of a single High dose of FT-002",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"GENETIC","FT-002","Comparison of different dosages of FT-002",[19,15,9],null,[30,34],{"name":31,"affiliation":32,"role":33},"Gezhi Xu","Eye & ENT Hospital of Fudan University","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":36,"role":33},"Ruifang Sui","Peking Union Medical College Hospital",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":28,"email":42},"Xinyan Li","CONTACT","+86-021-58206061","xinyan.li@fronteratherapeutics.com",{"name":44,"role":40,"phone":41,"phoneExt":28,"email":45},"Minghui Xue","minghui.xue@fronteratherapeutics.com",[47,63],{"facility":36,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":55,"coordinates":56},"Point",[57,58],116.39723,39.9075,{"lat":58,"lon":57},[61],{"name":62,"role":40,"phone":28,"phoneExt":28,"email":28},"Ruifang Sui, Professor",{"facility":64,"status":48,"city":65,"state":66,"zip":67,"country":52,"countryCode":53,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Eye & ENT hospital of Fudan university","Shanghai","Shanghai Municipality","200032",{"type":55,"coordinates":69},[70,71],121.45806,31.22222,{"lat":71,"lon":70},[74,76],{"name":75,"role":40,"phone":28,"phoneExt":28,"email":28},"Gezhi Xu, Professor",{"name":77,"role":40,"phone":28,"phoneExt":28,"email":28},"Jihong Wu, Professor",{"type":79,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[81,83,84],{"name":32,"class":82},"OTHER",{"name":36,"class":82},{"name":85,"class":82},"Henan Provincial People's Hospital","100506432","early-phase-1-gene-therapy-for-subjects-with-rpgr-mutation-associated-x-linked-retinitis-pigmentosa-100506432",false,"NCT05874310","Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa","An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.","Inclusion Criteria:\n\n1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ;\n\nExclusion Criteria:\n\n1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.","MALE","8 Years","45 Years",{"count":97,"type":98},18,"ESTIMATED","INTERVENTIONAL",[101],"EARLY_PHASE1","A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).",[104],"X-Linked Retinitis Pigmentosa","2023-05-23",{"date":107,"type":108},"2023-05-24","ACTUAL",{"date":110,"type":108},"2023-02-01",{"date":112,"type":98},"2027-11-01",{"name":5,"class":6},2]